PCTAIRE-2 Inhibitors
PCTAIRE-2 inhibitors represent a class of chemical compounds designed to specifically target and inhibit the activity of the protein kinase PCTAIRE-2 (also known as CDK16). PCTAIRE-2 is a member of the cyclin-dependent kinase (CDK) family, which plays a crucial role in regulating the cell cycle and various cellular processes such as cell division, transcription, and differentiation. PCTAIRE-2, in particular, is known to be involved in neuronal development, making it a significant target in neuroscience research.
PCTAIRE-2 inhibitors are designed to bind to the active site of the PCTAIRE-2 enzyme, disrupting its ability to phosphorylate target proteins and therefore impeding its normal cellular functions. This targeted inhibition can have a profound impact on cellular processes influenced by PCTAIRE-2, potentially leading to insights into the molecular mechanisms underlying neurological disorders and other conditions where PCTAIRE-2 is implicated. Researchers have been exploring the development and application of PCTAIRE-2 inhibitors as valuable tools in the laboratory to study cell signaling pathways, with the ultimate aim of better understanding the physiological and pathological processes governed by this kinase. By elucidating the role of PCTAIRE-2 in various cellular contexts, these inhibitors have the potential to contribute significantly to our knowledge of cell biology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib inhibits CDK17 by competing with ATP for binding to the catalytic site, thus preventing phosphorylation of target substrates. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol binds to CDK17 and inhibits its kinase activity, leading to cell cycle arrest. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
While primarily targeting CDK4/6, palbociclib can also inhibit CDK17, interfering with cell cycle progression. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a selective inhibitor that binds to CDK17, reducing its kinase activity and affecting cell cycle regulation. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $207.00 $246.00 $1025.00 $3065.00 | 1 | |
AT7519 interacts with the ATP binding pocket of CDK17, leading to inhibition of its kinase function. | ||||||
RGB-286638 | 784210-88-4 | sc-507523 | 250 mg | $285.00 | ||
RGB-286638 targets multiple CDKs including CDK17, disrupting cell cycle progression and transcriptional regulation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine competes with ATP for the active site of CDK17, thereby inhibiting its activity. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib has the potential to inhibit CDK17 by binding to its catalytic site, though it is more selective for CDK4/6. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
LEE011 (Ribociclib) can inhibit CDK17 by preventing ATP binding and kinase activity, affecting cell cycle regulation. | ||||||
P276-00 | 920113-03-7 | sc-477932 | 1 mg | $380.00 | ||
P276-00 inhibits CDK17 and disrupts cell cycle progression by blocking ATP binding to the kinase. | ||||||